These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1158 related items for PubMed ID: 23928189

  • 1. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun 15; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 3. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 15; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.
    Immunol Lett; 2014 Sep 15; 161(1):31-7. PubMed ID: 24792671
    [Abstract] [Full Text] [Related]

  • 7. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.
    Bone; 2015 Oct 15; 79():242-51. PubMed ID: 26103094
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):96-104. PubMed ID: 23791609
    [Abstract] [Full Text] [Related]

  • 10. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY, Cheon YH, Oh HM, Rho MC, Erkhembaatar M, Kim MS, Lee CH, Kim JJ, Choi MK, Yoon KH, Lee MS, Oh J.
    Bone; 2014 Mar 05; 60():104-11. PubMed ID: 24361669
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr 05; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 12. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH, Gu DR, Jin SH, Yoon CS, Ko W, Kim YC, Lee SH.
    Am J Chin Med; 2017 Apr 05; 45(8):1725-1744. PubMed ID: 29121799
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B.
    Int J Biochem Cell Biol; 2012 Jul 05; 44(7):1139-52. PubMed ID: 22521613
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.
    Biochem Biophys Res Commun; 2005 Apr 15; 329(3):839-45. PubMed ID: 15752732
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 15; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.
    Immunol Lett; 2012 Feb 29; 142(1-2):34-40. PubMed ID: 22193059
    [Abstract] [Full Text] [Related]

  • 20. Aminocoumarins inhibit osteoclast differentiation and bone resorption via downregulation of nuclear factor of activated T cells c1.
    Zheng T, Noh AL, Park H, Yim M.
    Biochem Pharmacol; 2013 Feb 01; 85(3):417-25. PubMed ID: 23123663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.